Non-small cell lung cancer
Immutep supports clinical research in advanced and metastatic non-small cell lung cancer, with interest in immunotherapy combinations built around pembrolizumab and chemotherapy for PD-L1-unselected disease.
- Immune checkpoint therapy
- Combination immuno-oncology
- Late-stage lung cancer
The sponsor’s oncology portfolio includes treatment strategies aimed at improving outcomes in metastatic lung cancer through immune-based regimens.
Head and neck cancer
Clinical activity also extends to metastatic head and neck squamous cell carcinoma, where the focus is on eftilagimod alpha in combination with pembrolizumab for advanced solid tumours.
- Squamous cell carcinoma
- Immune-based combination therapy
- Metastatic head and neck cancer
This area reflects a strong interest in immuno-oncology approaches for difficult-to-treat cancers of the upper aerodigestive tract.
Metastatic breast cancer
Immutep is involved in research for HER2-negative and HER2-low metastatic breast cancer, with studies centered on combining efti with paclitaxel and other standard treatments.
- HER2-negative disease
- HER2-low disease
- Taxane-based therapy
The sponsor’s breast cancer program focuses on advanced disease settings where immune modulation is paired with established chemotherapy backbones.
Autoimmunity
Beyond oncology, Immutep funds research in autoimmunity through investigation of immunosuppressive antibody approaches, indicating interest in immune regulation outside cancer.
- Immune suppression
- Healthy volunteer safety research
- Immune-mediated disease
This therapeutic domain broadens the sponsor’s portfolio into immune system modulation for non-oncologic conditions.
